Showing 4731-4740 of 9330 results for "".
- AMBI Now Part of Valeant Pharmaceuticalshttps://practicaldermatology.com/news/20121221-ambi_now_part_of_valeant_pharmaceuticals/2459653/Johnson & Johnson has sold the AMBI brand to Valeant Pharmaceuticals North America. Valeant is a multinational, pharmaceutical/OTC company based in Bridgewater, NJ.
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35 perce…
- Goldfaden MD to Donate to American Heart Association in 2013https://practicaldermatology.com/news/20121218-goldfaden_md_to_donate_to_american_heart_association_in_2013/2459656/Goldfaden MD plans to launch its Hands To Heart Anti-Aging Plus Brightening Hand Treatment in February 2013. In addition, ten percent of all proceeds from these purchases in February will be donated to the American Heart Association. The fast-absorbing cream helps fade dark spots and reduces the ap…
- PreCision Dermatology Adds to Board of Directorshttps://practicaldermatology.com/news/20121211-precision_dermatology_adds_to_board_of_directors/2459660/PreCision Dermatology, Inc. appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 27 years. Most recently, as the Executive Vice President of Constellation Pharmaceuticals, he also assumed …
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and conditions Galderma currently supplies those products …
- Tofacitinib Citrate Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121203-tofacitinib_citrate_approved_for_rheumatoid_arthritis/2459668/Pfizer Inc. received US FDA approval for XELJANZ (tofacitinib citrate) 5mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. XELJANZ may be used as monotherapy or in combination with me…
- Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infectionshttps://practicaldermatology.com/news/20121128-merz_inc_acquires_onmel_oral_treatment_for_toenail_fungal_infections/2459671/Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the company, ONMEL is the only FDA-approved oral treat…
- Jurlique Purely Bright Releases Clinical Resultshttps://practicaldermatology.com/news/20121128-jurlique_purely_bright_releases_clinical_results/2459672/Jurlique Purely Bright, a brightening system launched earlier this year, released clinical results on its product line. After 30 days, the system was clinically proven to help reduce dark spots. After 12 weeks, skin surface smoothness doubled at which point 80 percent of subjects noticed smoother, …
- Valeant Receives FTC Clearance For Medicis Acquisitionhttps://practicaldermatology.com/news/20121121-valeant_receives_ftc_clearance_for_medicis_acquisition/2459676/The US Federal Trade Commission (FTC) granted early termination of the waiting period surrounding the proposed acquisition of Medicis Pharmaceutical Corporation by Valeant Pharmaceuticals International, Inc., effective November 15, 2012. The proposed merger remains subject to other customary closin…
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.